Adolor begins Phase III with ADL 8-2698

ADLR began a U.S. placebo-controlled Phase III trial of its ADL 8-2698 oral non-absorbed small molecule opioid antagonist in 180 patients with post-operative ileus (temporary bowel paralysis following...